Saturday 17 October 2026
Export COCP’s income statement to Excel — free account
Cocrystal Pharma, Inc.
COCP Healthcare Biotechnology
In the quarter to June 2026, revenue fell 81.1%, EPS fell 15.0% and free cash flow fell 16.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.02
0.01
−0.97%
Follow COCP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | 0.00 |
P/S ratio |
— | — | 7.83 | 10.89 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (5.95) | (5.75) | |
P/B ratio |
— | — | 3.38 | 13.87 | |
Price to Tangible BV |
— | — | 0.00 | 0.00 | |
EV/Sales |
— | — | 5.16 | 9.21 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (1.21) | (1.54) | |
EV/FCF |
— | — | (1.21) | (1.54) | |
Quick Ratio |
5.47 | 3.53 | 2.48 | 1.14 | |
Current Ratio |
5.78 | 3.68 | 2.66 | 1.24 | |
Net Debt/EBITDA |
3.90 | 2.97 | 2.03 | 0.75 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.20 | 0.20 | |
Operating CF/Net income |
0.66 | 0.72 | 1.02 | 0.80 | |
Capex/Depreciation |
(0.13) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 609.33% | 2,040.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 537.78% | 1,092.38% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 37.33% | 87.62% | |
Graham Net Nets |
— | — | 0.19 | (0.03) | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (72.28%) | (72.38%) | |
Free Cash Flow Yield |
— | — | (54.62%) | (55.02%) | |
Revenue per Share |
0.00 | 0.00 | 0.02 | 0.01 | |
Operating CF per Share |
(0.12) | (0.15) | (0.17) | (0.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.12) | (0.15) | (0.17) | (0.18) | |
Cash per Share |
0.71 | 0.63 | 0.35 | 0.16 | |
Shareholders Equity per Share |
0.70 | 0.56 | 0.30 | 0.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.70 | 0.56 | 0.30 | 0.08 | |
Free Cash Flow |
(1.37) | (1.74) | (2.34) | (2.52) | |
Working Capital |
7.26 | 5.92 | 3.71 | 0.62 | |
Capital Expenditures |
(0.01) | 0.00 | — | — | |
Net Current Asset Value |
6.01 | 4.75 | 2.63 | (0.37) | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.58 | 0.96 | 1.10 | 1.19 | |
Average Payables |
1.42 | 2.00 | 1.75 | 1.89 | |
Average Assets |
13.34 | 11.58 | 9.04 | 6.58 | |
Average Common Equity |
10.19 | 7.93 | 5.71 | 3.19 |
Columns are period end dates